中国经济网12月22日讯 日前，河南省医药集中采购平台在其官网公示了三份药企公开致歉信。哈尔滨誉衡制药有限公司、吉林四环制药有限公司、珠海经 济特区粤康医药有限公司分别就各自涉及的不合规交易行为公开致歉。 吉林四环制药有限 吉林四环(2025) 016 号 公开致歉声明 我公司生产的产品"脑苷肌肤注射液",其合作 在不合规交易行为,违背了商业道德准则,扰乱了市 我们深表歉意! 事件发生后,我司高度重视,第一时间成立专I 商的全流程展开深入排查,严格落实与履行全链条1 行为坚决整改,并严肃追究相关人员责任,为彻底杜 生,我司已迅速制定并落实以下整改措施: 3. 加强合规体系建设:已系统性修订并强化了* 明确了违规行为的违约责任与处罚机制,并组织全f 伴进行专项培训与考核。 4. 解除涉及此事件相关人员的劳动合同。 我司郑重承诺:我们将以此为深刻的教训,举- 第二 壮信权益" 出空白 人击出 小人 小人 小 界的人，网 网 红 红 百 时 小 内 日 ， 上 叫 张 他 让 " 动 哈 生 - 决杜绝任何形式的不正当竞争行为,自觉维护医药则 为河南省乃至全国的医疗卫生事业健康发展贡献应2 我们再次为此次事件所造成 ...

Core Viewpoint - The article highlights the ongoing issues with the timely supply of drugs and medical devices following centralized procurement in various regions of China, indicating a significant number of products have not established delivery relationships post-selection, which raises concerns about the reliability of selected suppliers [1][9]. Group 1: Issues with Drug Supply - As of May 31, 2023, 443 drug specifications have not established timely delivery relationships after centralized procurement in Guangzhou, with nearly 70% of the 221 identified underperforming products having a delivery rate of 0 [9][10]. - The Hebei Provincial Medical Procurement Center has announced that certain companies will be rated as "generally" untrustworthy due to inadequate delivery services, including Suzhou Terui Pharmaceutical and Lizu Group, which are involved in multiple national procurement batches [2][5]. Group 2: Specific Products and Companies - Lizu Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, a significant drop from its previous market price of 700-800 yuan, reflecting a price reduction of over 90% [2]. - Northland Pharmaceutical's iohexol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [3]. Group 3: Regulatory Framework and Consequences - The Hebei Provincial Medical Procurement Center has established a credit evaluation system for pharmaceutical pricing and procurement, categorizing untrustworthy behavior into four levels: "general," "medium," "serious," and "particularly serious" [7]. - Companies identified as untrustworthy may face consequences such as written warnings, risk notifications on procurement platforms, and restrictions on the procurement qualifications of related drugs and materials [7]. Group 4: Broader Supply Issues - Beyond medical institutions, there are also reported supply shortages in designated pharmacies, with 422 drugs not supplied, affecting various products and involving 289 manufacturers [8].

Policy Developments - The National Healthcare Security Administration has revised the medical price and procurement credit evaluation system to combat commercial bribery and encourage integrity among pharmaceutical companies [2][3] - The revised system aims to increase the cost of dishonesty for companies and promote compliance, quality improvement, and effective market participation through collective procurement and national negotiations [2][3] Industry Updates - The internal whistleblower reward system for drug and medical device quality safety has been announced, incentivizing individuals who provide clear evidence of violations that lead to administrative penalties or criminal prosecution [4] - A notification has been issued to promote pain relief services during childbirth across various medical institutions, with goals set for 2025 and 2027 to ensure comprehensive service availability [5] Company News - Puluo Pharmaceutical has received approval for the listing application of Succinic Acid Desvenlafaxine, a third-generation antidepressant for treating major depressive disorder [7] - China Pharmaceutical has obtained a drug registration certificate for Sulfhydryl Clopidogrel Tablets, aimed at secondary prevention of atherosclerotic thromboembolic events in specific patient groups [8] - Shanghai Sipurei Pharmaceutical Technology has completed over 200 million RMB in angel round financing, with funds allocated for preclinical and early clinical development [11] - Kelun Pharmaceutical's subsidiary plans to raise approximately 1.943 billion HKD through a share placement to support product development and operational needs [12] - Merck KGaA has entered a strategic partnership with Zai Lab to commercialize a recombinant human thyroid-stimulating hormone in mainland China [14] - China National Pharmaceutical Group has established a technology innovation research institute with a registered capital of 1 billion RMB, focusing on various research and development activities [15] Management Changes - Tongrentang Technology announced the resignation of its chairman and general manager due to work changes, indicating potential shifts in company leadership [17]